| 今开：0.9822 | 昨收：0.9822 |
| 最高：0.9999 | 最低：0.9257 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：1.74722062E8 |
里格尔制药(RIGL)03-30 04:15
$里格尔制药(RIGL)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000905148-24-001015 Size: 9 KB 网页链接查看全文
里格尔制药(RIGL)05-08 04:15
$里格尔制药(RIGL)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-24-007041 Act: 34 Size: 9 MB 网页链接查看全文
里格尔制药(RIGL)02-15 03:35
$里格尔制药(RIGL)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-24-001234 Act: 34 Size: 90 KB 网页链接查看全文
里格尔制药(RIGL)04-12 20:15
$里格尔制药(RIGL)$ 8-K Current report, item 1.01 Accession Number: 0001104659-24-046527 Act: 34 Size: 200 KB 网页链接查看全文
里格尔制药(RIGL)03-02 08:25
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000848 Size: 8 KB 网页链接查看全文
里格尔制药(RIGL)03-30 04:15
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001016 Size: 5 KB 网页链接查看全文
里格尔制药(RIGL)04-11 04:55
$里格尔制药(RIGL)$ DEF 14A Other definitive proxy statements Accession Number: 0001140361-24-019133 Act: 34 Size: 11 MB 网页链接查看全文
里格尔制药(RIGL)03-06 05:15
$里格尔制药(RIGL)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001558370-24-002475 Act: 34 Size: 12 MB 网页链接查看全文
里格尔制药(RIGL)03-02 08:25
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-000851 Size: 8 KB 网页链接查看全文
里格尔制药(RIGL)02-22 21:05
$里格尔制药(RIGL)$ 8-K Current report, items 1.01 and 2.01 Accession Number: 0001104659-24-026338 Act: 34 Size: 204 KB 网页链接查看全文
智通财经APP获悉，Rigel制药公司(RIGL.US)周四表示，该公司用于治疗复发或难治性(R/R)急性髓系白血病(AML)患者的Rezlidhia(olutasidenib)胶囊已获美国食品药品监督管理局批准。Rigel称，这一批准得到了2期试验数据的支持。受此消息影响... 网页链接
智通财经APP获悉，H.C. Wainwright分析师Joseph Pantginis将Rigel Pharmaceuticals(RIGL.US)的目标价从8美元上调至11美元，维持“买入”评级。该公司此前公布了治疗COVID-19住院患者的Tavalisse (fostamatinib)的2期临床试验的积极结果... 网页链接
$里格尔制药(RIGL)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-24-058017 Act: 34 Size: 337 KB 网页链接
$里格尔制药(RIGL)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-24-007041 Act: 34 Size: 9 MB 网页链接
$里格尔制药(RIGL)$ 8-K Current report, item 1.01 Accession Number: 0001104659-24-046527 Act: 34 Size: 200 KB 网页链接
$里格尔制药(RIGL)$ ARS Annual Report to Security Holders Accession Number: 0001140361-24-019150 Act: 34 Size: 2 MB 网页链接
$里格尔制药(RIGL)$ DEF 14A Other definitive proxy statements Accession Number: 0001140361-24-019133 Act: 34 Size: 11 MB 网页链接
$里格尔制药(RIGL)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001140361-24-019134 Act: 34 Size: 1 MB 网页链接
$里格尔制药(RIGL)$ PRE 14A Other preliminary proxy statements Accession Number: 0001140361-24-016625 Act: 34 Size: 11 MB 网页链接
$里格尔制药(RIGL)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0000905148-24-001015 Size: 9 KB 网页链接
$里格尔制药(RIGL)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000905148-24-001016 Size: 5 KB 网页链接
$里格尔制药(RIGL)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001558370-24-002475 Act: 34 Size: 12 MB 网页链接